Home Featured Page 162

Featured

Latest

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Chronic Pain, Illicit Markets, and a Preventable Pipeline to Addiction

MDMA: Rolling from Counterculture to the Clinic Counter

PT337 – Lauren Katalinich & Anya Oleksiuk – The Psychedelic Society:...

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel...

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And...

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for...

FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK...

PT336 – Sisi Li, Ph.D. – Porta Sophia: Psychedelic Prior Art

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic...

Psychedelic Research Bulletin: June 2022

Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules...

1...161162163...305 Page 162 of 305

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Chronic Pain, Illicit Markets, and a Preventable Pipeline to Addiction

MDMA: Rolling from Counterculture to the Clinic Counter

PT337 – Lauren Katalinich & Anya Oleksiuk – The Psychedelic Society:...

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel...

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And...

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for...

FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK...

PT336 – Sisi Li, Ph.D. – Porta Sophia: Psychedelic Prior Art

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic...

Psychedelic Research Bulletin: June 2022

Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules...

EDITOR PICKS

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY